Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL870814 | 0.77 | MCL1 (0.33) | MCL1BCL2 | |
| SCHEMBL2252786 | 0.77 | MCL1 (0.33) | MCL1BCL2 | |
| SCHEMBL9913514 | 0.75 | APLNR (0.33) | — | |
| SCHEMBL18519371 | 0.74 | ESR2 (0.40) | MCL1BCL2 | |
| SCHEMBL14810191 | 0.73 | BRD4 (0.43) | — | |
| SCHEMBL31352403 | 0.73 | CRBN (0.39) | MCL1BCL2 | |
| SCHEMBL31623264 | 0.72 | HSD11B1 (0.33) | MCL1 | |
| SCHEMBL428708 | 0.72 | — | — | |
| SCHEMBL3491883 | 0.71 | MCL1 (0.40) | MCL1BCL2 | |
| SCHEMBL8532532 | 0.70 | SRD5A2 (0.33) | MCL1BCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210252035-A1 | SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS | Epizyme, Inc. | 2021-08-19 | — | — | US | disclosed |
| US-10400005-B2 | Substituted purine compounds | Epizyme, Inc. (US) | 2019-09-03 | — | — | US | disclosed |
| US-20180127451-A1 | SUBSTITUTED PURINE COMPOUNDS | Epizyme, Inc. | 2018-05-10 | — | — | US | disclosed |
| US-20180127451-A1 | SUBSTITUTED PURINE COMPOUNDS | Epizyme, Inc. | 2018-05-10 | — | — | US | disclosed |
| US-9688714-B2 | Substituted purine compounds | Epizyme, Inc. (US) | 2017-06-27 | — | — | US | disclosed |
| US-9688714-B2 | Substituted purine compounds | Epizyme, Inc. (US) | 2017-06-27 | — | — | US | disclosed |
| EP-2646444-B1 | SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS AS MODULATORS OF EPIGENETIC ENZYMES | EPIZYME INC (US) | 2016-03-16 | — | — | EP | disclosed |
| US-20150366893-A1 | SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS | Epizyme, Inc. (US) | 2015-12-24 | — | — | US | disclosed |
| US-20150366893-A1 | SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS | Epizyme, Inc. (US) | 2015-12-24 | — | — | US | disclosed |
| US-9096634-B2 | Substituted purine and 7-deazapurine compounds | Epizyme, Inc. (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096634-B2 | Substituted purine and 7-deazapurine compounds | Epizyme, Inc. (US) | 2015-08-04 | — | — | US | disclosed |
| WO-2015003131-A1 | SUBSTITUTED PURINE COMPOUNDS | Epizyme, Inc. (US) | 2015-01-08 | — | — | WO | disclosed |
| WO-2014152261-A1 | SUBSTITUTED 7-DEAZAPURINE COMPOUNDS | Epizyme, Inc. (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20140051654-A1 | Substituted Purine and 7-Deazapurine Compounds | Epizyme, Inc. (US) | 2014-02-20 | — | — | US | disclosed |
| US-8580762-B2 | Substituted purine and 7-deazapurine compounds | Epizyme, Inc. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580762-B2 | Substituted purine and 7-deazapurine compounds | Epizyme, Inc. (US) | 2013-11-12 | — | — | US | disclosed |
| WO-2012075381-A1 | SUBSTITUTED PURINE AND 7 - DEAZAPURINE COMPOUNDS AS MODULATORS OF EPIGENETIC ENZYMES | Epizyme, Inc. (US) | 2012-06-07 | — | — | WO | disclosed |
| US-20120142625-A1 | Substituted Purine And 7-Deazapurine Compounds | Epizyme, Inc. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120142625-A1 | Substituted Purine And 7-Deazapurine Compounds | Epizyme, Inc. (US) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210252035-A1 | SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS | TPMT, DIMT1, DAZAP1 | MCL1 553/4885BCL2 4181/4885 |
| US-20150366893-A1 | SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS | TPMT, DIMT1, DAZAP1 | MCL1 553/4885BCL2 4181/4885 |
| US-20140051654-A1 | Substituted Purine and 7-Deazapurine Compounds | TPMT, DIMT1, DAZAP1 | MCL1 553/4885BCL2 4181/4885 |
| US-20180127451-A1 | SUBSTITUTED PURINE COMPOUNDS | DIMT1, DOT1L, TPMT | MCL1 447/4885BCL2 4128/4885 |
| US-20120142625-A1 | Substituted Purine And 7-Deazapurine Compounds | TPMT, DIMT1, DAZAP1 | MCL1 553/4885BCL2 4181/4885 |
| US-10400005-B2 | Substituted purine compounds | DIMT1, DOT1L, TPMT | MCL1 447/4885BCL2 4128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.